Health · 3 views
Targeting immune overactivity in Down syndrome shows promise in phase 2 clinical trial
In a first-of-its-kind clinical trial, researchers at the Linda Crnic Institute for Down Syndrome (Crnic Institute) at the University of Colorado Anschutz found that a medication targeting immune overactivity in people with Down syndrome…
AI Summary
Researchers at the Linda Crnic Institute for Down Syndrome at the University of Colorado Anschutz conducted a phase 2 clinical trial of tofacitinib, a JAK inhibitor that blocks signals involved in immune responses and inflammation. The study found that the medication reduced underlying inflammation in people with Down syndrome. Participants also showed improvements in inflammatory skin conditions. The results were published in Cell Reports Medicine and suggest new research directions for brain health and Alzheimer’s disease.
AI summaries can be wrong sometimes—always verify important details using the source article.
How AI & Automation are usedMore from Health
Continue reading recent Health coverage
- STAT+: Influential preventive services panel to meet for first time in more than a yearContinue reading
- Quadruple Agonist Reduced Weight Without Major Muscle Loss in Mid-Stage TrialContinue reading
- Brain model offers new explanation for memory formation and how dementia disrupts itContinue reading
- Should All Adults Be Screened for Lipoprotein(a)?Continue reading
Support HappeningNow
Independent AI-powered news analysis is reader-supported. Your contribution helps cover infrastructure, summaries, and continued platform development.
Support HappeningNow